CONTACT ME

© 2017 By Marita Zimmermann.

I am a health economist and global health researcher, and am passionate about using high quality research methods to increase value in health.

 

I believe that health care is a human right, and we do not have unlimited resources for health. My goal is to use econometric, epidemiologic, and modeling methods to figure out how to get the most bang for our health care buck.

 

I aim to work on projects that have current usability or policy relevance, and can influence real change in healthcare for patients in real time.

 
HOW CAN MY WORK HELP YOU?
EXPERIENCE
 
EDUCATION
 
PUBLICATIONS
 
Peer Reviewed Manuscripts 

Assessment tool for establishing local pharmaceutical manufacturing in low- and middle-income countries.

Zimmermann M, Adamson B, Lam-Hine T, Rennie T, Stergachis, A.

Int J Pharm Prac. 2018 Aug;26(4)364-368.

Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis.

Zimmermann M, Vodicka E, Holman AJ, Garrison LP.

Journal of Medical Economics. 2018 Jul;21(7)712–720.

Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.

Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J.

Journal of Drugs in Dermatology. 2018 Jul;17(7)750–756.

Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up.

Garrison L, Zimmermann M, Young C, Crittendon J, Généreux P.

Cardiovascular Revascularization Medicine. 2017 Mar;18(2)86–90.

Zimmermann M, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, Garrison LP, Chung MH. Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya. Cost Ef Resour Alloc. 2017 Dec;15(1)13.

Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.

Duintjer Tebbens, R.J., Zimmermann, M., Pallansch, M.A., Thompson, K.

Food Environ Virol (2017). doi:10.1007/s12560-017-9314-4

 

Misclassification of Antiretroviral Treatment Failure Using WHO 2006 and 2010/2013 Immunologic Criteria in HIV-Infected Children and Adolescents in Western Kenya.

Dufort EM, DeLong AK, Mann M, Nyandiko WM, Ayaya SO, Hogan JW, Kantor R.

Infectious Diseases Society. 2017 Sept;6(3)285-288.

Costs of integrating cervical cancer screening at an HIV clinic in Kenya.

Vodicka EL, Babigumira JB, Mann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Garrison LP Jr, Chung MH.

Int J Gynaecol Obstet. 2017 Feb;136(2):220-228.

 

Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis.

Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, Garrison LP Jr, Stergachis A.

Drug Saf. 2016 Sep;39(9):859-72. 


Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia.
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, Babigumira JB, Garrison LP, Stergachis A.
Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1052-60.


The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach.
Chambers J, Généreux P, Lee A, Lewin J, Young C, Crittendon J, Mann M, Garrison LP.
Ther Adv Cardiovasc Dis. 2016 Apr;10(2):74-85. 


Misclassification of Antiretroviral Treatment Failure Using WHO 2006 and 2010/2013 Immunologic Criteria in HIV-Infected Children and Adolescents in Western Kenya.
Dufort EM, DeLong AK, Mann M, Nyandiko WM, Ayaya SO, Hogan JW, Kantor R.
J Pediatric Infect Dis Soc. 2016 Apr 29. 

 

The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification.
Garrison LP Jr, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG.
Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):406-12.


HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.
Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, Cu-Uvin S, D'Aquila R, Frenkel L, Fiscus S, Coombs R; ACTG A5077 Study Team.
PLoS One. 2014 Apr 3;9(4):e93537. 

Antiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure.
Mann M, Diero L, Kemboi E, Mambo F, Rono M, Injera W, Delong A, Schreier L, Wools-Kaloustian K, Sidle J, Buziba N, Kantor R.
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):220-4.

 

Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.Land S, Zhou J, Cunningham P, Sohn AH, Singtoroj T, Katzenstein D, Mann M, Sayer D, Kantor R.

J Int AIDS Soc. 2013 Jul 10;16:18580.


How does use of a prescription monitoring program change pharmacy practice?
Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD.
J Am Pharm Assoc (2003). 2013 May-Jun;53(3):273-81.

 

Effects of political conflict-induced treatment interruptions on HIV drug resistance.

Mann M, Lurie MN, Kimaiyo S, Kantor R.

AIDS Rev. 2013 Jan-Mar;15(1):15-24. 


How does use of a prescription monitoring program change medical practice?
Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD.
Pain Med. 2012 Oct;13(10):1314-23.


Life after the ban: an assessment of US syringe exchange programs' attitudes about and early experiences with federal funding.
Green TC, Martin EG, Bowman SE, Mann MR, Beletsky L.
Am J Public Health. 2012 May;102(5):e9-16.

SKILLS